SCHEMBL5947209

SCHEMBL5947209

FCCCOc1cccc(CNCCc2c[nH]c3cccc(Cl)c23)c1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.52
▸ HTR6 P50406 3/20 0.47
▸ HTR2A P28223 2/20 0.47
▸ HTR1A P08908 1/20 0.47
▸ DRD2 P14416 1/20 0.47
▸ HTR2C P28335 1/20 0.47
▸ HTR7 P34969 1/20 0.47
▸ SLC6A4 P31645 1/20 0.43
▸ MC5R P33032 1/20 0.43
▸ MC3R P41968 1/20 0.43
▸ MC1R Q01726 1/20 0.43
▸ MEN1 O00255 1/20 0.42
▸ GPR84 Q9NQS5 1/20 0.42
▸ BCHE P06276 4/20 0.42
▸ MAPT P10636 2/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ ACHE P22303 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.40
▸ LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5947178 0.96 KMT2A (0.52) KMT2AHTR6HTR2AHTR1ADRD2
SCHEMBL5947965 0.90 KMT2A (0.54) KMT2AHTR6HTR2AHTR1ADRD2
SCHEMBL5947441 0.87 KMT2A (0.51) KMT2AHTR6HTR2AHTR1ADRD2
SCHEMBL5947930 0.87 HTR6 (0.55) KMT2AHTR6HTR2AHTR1ADRD2
SCHEMBL5947355 0.86 KMT2A (0.58) KMT2AHTR6HTR2AHTR1ADRD2
SCHEMBL5947455 0.85 HTR6 (0.54) KMT2AHTR6HTR2AHTR1ADRD2
SCHEMBL5947451 0.84 KMT2A (0.57) KMT2AHTR6HTR2AHTR1ADRD2
SCHEMBL5947089 0.84 KMT2A (0.55) KMT2AHTR6HTR2AHTR1ADRD2
SCHEMBL2532828 0.84 HTR6 (0.57) KMT2AHTR6HTR2AHTR1ADRD2
SCHEMBL5947246 0.83 KMT2A (0.59) KMT2AHTR6HTR2AHTR1ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor CHEN ZHAOGEN 2006-01-12 — — US claimed
CN-1610547-A N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor LILLY CO ELI (US) 2005-04-27 — — CN claimed
EP-1379239-A2 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2004-01-14 — — EP claimed
WO-2002078693-A2 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2002-10-10 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor HTR6, HTR2C, HTR1B KMT2A 1269/4885HTR6 1/4885HTR2A 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback